The aim of present study is to formulate an intravenous injection of Vancomycin Hydrochloride. It was belongs to the category of antibiotic and it was widely used in staphylococcal endocarditis. The main objective of the study was to develop rapid reconstituted formulation of Vancomycin Hydrochloride by using lyophilization technology. The lyophilization was carried in different batches of the Vancomycin Hydrochloride were prepared with varying the excipients and its concentration while keeping the lyophilization cycle constant. An optimized lyophilization cycle of 36 hours was achieved. The optimized lyophilized product was subjected to in vitro parameters such as cake appearance, reconstitution time, PH, assay, RS, particulate matter, water content, IR, color value, % light transmittance, DSC. After considering all product characteristics batch-6 was considered as an optimized formulation. All the in-vitro evaluation parameters compiled the limits as per the specification of USP. Scale up batch was done by increasing the batch size. Accelerated stability studies were also conducted and from the result it was concluded that the scale up formulation was found to be stable. Finally, it was concluded that the lyophilization is a suitable technique to increase reconstitution the Vancomycin Hydrochloride of injection (500 mg/vial).

Zolmitriptan is widely used as Anti migraine agent. They are formulated as oral disintegrating tablets which show better patient acceptability and compliance with improved efficacy when compared with conventional dosage forms. Based on various studies carried out we have arrived at the following conclusions: Direct compression was used for the preparation of oral disintegrating tablets of Zolmitriptan Based on the preliminary studies various formulation trials (F1-F9) were carried out with different concentrations of superdisintegrants and diluents. From the various formulations it was concluded that the formulation F9, the reproducibility batch of F8 was finalized as the optimized formula. Formulation F9 showed satisfactory results with various physicochemical evaluation parameters like Hardness, Percentage weight loss, Disintegration time, Dissolution profile, Assay and Moisture content when compared with the marketed product. When subjected to accelerated stability studies the tablets were found to be stable.

Dengue is a viral vector borne disease that has become a serious health problem worldwide and no treatment or vaccine is available for its prevention. The aim of the study was to evaluate the efficacy and safety of a novel herbal liquid formulation “DENPAP®”. The toxicity study was performed to evaluate the oral acute toxicity of DENPAP® in Wistar rats as per OECD 425 guidelines: up and down procedure method. The efficacy study was carried out to identify the efficacious dose of DENPAP® for Anti-Thrombocytopenic effect in Chemical (Cylcophosphamide) induced Thrombocytopenia model in Sprague Dawley rats for a period of 14 days. The acute toxicity study was carried out in Wistar Albino rats at different doses for a period of 14 days and it was concluded that the LD50 value for DENPAP® was more than 2000 mg/kg. The efficacy study was carried out in Sprague Dawley rats for a period of 14 days and from this study it was concluded that the platelet counts of the animals increased in comparison to that of Cylcophosphamide induced Thrombocytopenia controls. From this study the LD50 for DENPAP® was obtained and the platelet count of animals in the group treated with DENPAP® increased after 3-5 days post dosing indicating its potential antithrombocytopenic effect.

Dialysis patient lose protein during dialysis along with inability of the body to use and process amino acids due to kidney disease leading to re­quirement of higher protein demand than the av­erage healthy adult. In the pre-dialysis and dialysis period the dietary approach in the different phases of chronic renal insufficiency (CRI) has been highly controversial. Lack of protein in dialysis patient will result in the development of PEM, increased mor­tality and decreased physical functioning and qual­ity of life [1,2]. It is highly important to assess the nutritional status and to identify patients at risk to prevent and treat malnutrition in dialysis patients.

Herbal preparations are advantageous than the allopathic medicines. They have multidimensional usage i.e. a single herbal formulation can be used for variety of ailments. They have low toxicity when compared to allopathic medications and can be prepared at low cost. But herbal formulations have their own limitations. There is need of standardization. This work involves the preparation and standardization of a new herbal formulation panchaudara churna. The standardization of churna include microscopy, determination of physico-chemical properties like extractive values, ash values, micromeritic properties, total viable aerobic count, preliminary phytochemical screening, The Poly herbal tablets can be prepared from Poly herbal churna for better long shelf life, mask the bitter taste of churna and easily swallow able compared to churna. Panchaudara tablets are prepared by the wet granulation and compression of the churna. The preformulation studies on the granules show that granules have required moisture content, good compression properties and they are free flowing. Thus they can be compressed to a tablet. The tablets are evaluated as per Indian Pharmacopoeia. The evaluation of panchaudara tablets included weight variation test, friability test, and disintegration test, the dissolution test is not needed because it is cumbersome. The tablets can be used for the same diseases which are treated by churna.